<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106049</url>
  </required_header>
  <id_info>
    <org_study_id>Adiponectin in NAFLD</org_study_id>
    <nct_id>NCT05106049</nct_id>
  </id_info>
  <brief_title>Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.</brief_title>
  <official_title>Early Detection of Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease by Measuring Serum Adiponectin Level.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early detection of renal impairment in patients with non-alcoholic fatty liver disease and&#xD;
      its correlation with serum Adiponectin level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international&#xD;
      inc., USA&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.</measure>
    <time_frame>baseline</time_frame>
    <description>measure level of serum Adiponectin in non-alcoholic fatty liver patients to detect early renal impairment.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>cases</arm_group_label>
    <description>non-alcoholic fatty liver patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>healthy persons</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum Adiponectin</intervention_name>
    <description>serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        cases are Non-alcoholic fatty liver patients who do not having any other health problem.&#xD;
&#xD;
        control group is healthy individuals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with fatty liver aged from 18 to 60 yrs either diabetic or not .&#xD;
&#xD;
          -  Patient with normal echogenic kidney in ultrasound and eGFR more than 60&#xD;
             mL/min/1.73m2.&#xD;
&#xD;
          -  The Control group are completely healthy subjects without any systemic or liver and&#xD;
             kidney affection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients less than 18 yrs &amp; more than 60 yrs .&#xD;
&#xD;
          -  All patients having any other causes of renal and hepatic disease rather than Diabetes&#xD;
             and having any other systemic problem.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Hassan, Profissor.as</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hend Abdelrheem, Resident</last_name>
    <phone>01011062442</phone>
    <email>hendabdelrheem@gmail.com</email>
  </overall_contact>
  <results_reference>
    <citation>Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res. 2002 Sep;34(9):469-74. Review.</citation>
    <PMID>12384822</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hend Abdelrheem Ahmed</investigator_full_name>
    <investigator_title>Hend Abdelrheem</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://doi.org/10.1155/2020/6630296</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

